Evaluation of resveratrol and N-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model

Pediatr Blood Cancer. 2014 Apr;61(4):740-2. doi: 10.1002/pbc.24780. Epub 2013 Sep 20.


Fanconi anemia (FA) patients suffer from progressive bone marrow failure and often develop cancers. Previous studies showed that antioxidants tempol and resveratrol (RV) delayed tumor onset and reduced hematologic defects in FA murine models, respectively. Here we tested whether antioxidants N-acetylcysteine (NAC) or RV could delay cancer in tumor prone Fancd2(-/-) /Trp53(+/-) mice. Unlike tempol, neither compound had any significant chemopreventive effect in this model. We conclude that not all anti-oxidants are chemopreventive in FA. In addition, when given to Fancd2(-/-) mice, NAC helped maintain Fancd2(-/-) KSL cells in quiescence while tempol did not. The mechanisms behind the different actions of these antioxidants await further investigation.

Keywords: Fanconi anemia; N-acetylcysteine; antioxidants; chemoprevention; resveratrol.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetylcysteine / therapeutic use*
  • Animals
  • Antioxidants / therapeutic use*
  • Fanconi Anemia / genetics
  • Fanconi Anemia / pathology
  • Fanconi Anemia / prevention & control*
  • Fanconi Anemia Complementation Group D2 Protein / physiology*
  • Flow Cytometry
  • Free Radical Scavengers / therapeutic use*
  • Mice
  • Mice, Knockout
  • Resveratrol
  • Stilbenes / therapeutic use*
  • Tumor Suppressor Protein p53 / physiology*


  • Antioxidants
  • Fancd2 protein, mouse
  • Fanconi Anemia Complementation Group D2 Protein
  • Free Radical Scavengers
  • Stilbenes
  • Tumor Suppressor Protein p53
  • Resveratrol
  • Acetylcysteine